We are inspired by a vision for the future in which data, computing, networks, and other digital and deep technologies deliver meaningful outcomes and insight for improving health and the provision of care.
We invest in both solutions intended for use in the diagnosis or cure of disease and solutions designed to help healthcare organizations - be them hospitals, biopharmas, insurers, etc. - be better at what they do.
We see our sweet spot at seeding founders who are marrying in-depth understanding of the complex network of healthcare system participants with meaningful engineering innovation, advanced data science, and information technology-enabled products and services. We look for and invest in founders determined to effectively and efficiently serve these participants on the european continent, where we are based, and internationally.
In our investment criteria and process, we are informed by a Stanford-born methodology of health technology innovation known as Biodesign. Since 2001, Biodesign has proven to de-risk the process of new venture creation by applying a need-driven and value-based approach to reinventing healthcare with the help of technology. To learn more about the methodology, head to The Student Guide to Biodesign, developed by a team of Stanford instructors and students who are passionate about education and making high-quality learning materials available and accessible to all.
We invest in european companies as well as in selected non-european companies with ties to europe. Wherever they are, our goal is to help founders ready their companies to raise series A capital, and to access international markets.
To learn more about our process, click here.